Lumiracoxib in the treatment of osteoarthritis, rheumatoid arthritis and acute postoperative dental pain: Results of three dose-response studies

Current Medical Research and Opinion

Volumn 21, Issue 1, 2005, Pages 151-161

  Schnitzer, Thomas J ^a   Fricke Jr , James R ^b   Gitton, Xavier ^c   Jayawardene, Sumedha ^c   Sloan, Victor S ^c  

^a NORTHWESTERN UNIVERSITY   (United States)

^b Austin Oral Surgery Associates   (United States)

^c NOVARTIS PHARMA AG   (Switzerland)

Author keywords

Cyclo oxygenase; Dental pain; Lumiracoxib; Osteoarthritis; Rheumatoid arthritis

Indexed keywords

DICLOFENAC; LUMIRACOXIB; PARACETAMOL; PLACEBO;

ABDOMINAL DISTENSION; ABDOMINAL PAIN; ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANALGESIC ACTIVITY; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BREAST CANCER; BRONCHOSPASM; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DENTAL SURGERY; DIARRHEA; DISEASE EXACERBATION; DIZZINESS; DOSE TIME EFFECT RELATION; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; DYSPEPSIA; EDEMA; FATIGUE; FEMALE; HEADACHE; HIP OSTEOARTHRITIS; HUMAN; HYPERTENSION; HYPOXIA; KNEE OSTEOARTHRITIS; LIVER DYSFUNCTION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; PATIENT COMPLIANCE; PHASE 2 CLINICAL TRIAL; POSTOPERATIVE PAIN; PRURITUS; PYELONEPHRITIS; RANDOMIZED CONTROLLED TRIAL; RHEUMATOID ARTHRITIS; RHINOPHARYNGITIS; TOOTH PAIN; VESTIBULAR DISORDER; VOMITING;

ADOLESCENT; ADULT; AGED; ANALYSIS OF VARIANCE; ARTHRITIS, RHEUMATOID; CLINICAL TRIALS, PHASE II; CYCLOOXYGENASE INHIBITORS; DICLOFENAC; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; LOGISTIC MODELS; MALE; MIDDLE AGED; MULTICENTER STUDIES; ORGANIC CHEMICALS; OSTEOARTHRITIS; PAIN, POSTOPERATIVE; RANDOMIZED CONTROLLED TRIALS; TOOTH EXTRACTION; TREATMENT OUTCOME;

EID: 14744281305     PISSN: 03007995     EISSN: None     Source Type: Journal    
DOI: 10.1185/030079904X20231     Document Type: Article

References (28)

1. Meade EA, Smith WL, DeWitt DL. Differential inhibition of prostaglandin endoperoxide synthase (cyclooxygenase) isoenzymes by aspirin and other non-steroidal anti-inflammatory drugs. J Biol Chem 1993;268:6610-4
2. Warner TD, Giuliano F, Vojnovic I, Bukasa A, Mitchell JA, Vane JR. Nonsteroid drug selectivities for cyclo-oxygenase-1 rather than cyclo-oxygenase-2 are associated with human gastrointestinal toxicity: a full in vitro analysis. Proc Natl Acad Sci USA 1999;96:7563-8
3. Cryer B. Nonsteroidal anti-inflammatory drugs and gastrointestinal disease. In: Feldman M, Scharschmidt BF, Sleisenger MH, editors. Sleisenger and Fortran's gastrointestinal and liver disease: pathophysiology/diagnosis/ management, vol. 1, 6th ed. Philadelphia: WB Saunders; 1998. p. 343-57
4. Crofford LJ, Lipsky PE, Brooks P, Abramson SB, Simon LS, van de Putte LB. Basic biology and clinical application of specific cyclooxygenase-2 inhibitors. Arthritis Rheum 2000;43:4-13
5. Bombardier C, Laine L, Reicin A, et al. for the VIGOR Study Group. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. New Engl J Med 2000;343:1520-8
6. Goldstein JL, Correa P, Zhao WW, et al. Reduced incidence of gastroduodenal ulcers with celecoxib, a novel cyclooxygenase-2 inhibitor, compared to naproxen in patients with arthritis. Am J Gastroenterol 2001;96:1019-27
7. Marshall PJ, Berry JC, Wasvary J, et al. The in vitro and in vivo selectivity of COX189, a new and highly selective inhibitor of COX-2. Ann Rheum Dis 2002;61(Suppl 1):259 [abstract SAT0013]
8. Scott G, Rordorf C, Blood P, Branson J, Milosavljev S, Greig G. Dose escalation study to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of COX189 in healthy subjects. Ann Rheum Dis 2002;61(Suppl. 1):242 [abstract FR1300]
9. Hartmann S, Scott G, Rordorf C, Campestrini J, Branson J, Keller U. Lumiracoxib demonstrates high absolute bioavailability in healthy subjects. In: Tulunay FC, Orme M, editors. European collaboration: towards drug development and rational drug therapy. Proceedings of the Sixth Congress of the European Association for Clinical Pharmacology and Therapeutics. Berlin: Springer-Verlag; 2003. p.124 [abstract P-199]
10. Scott G, Rordorf C, Milosavljev S, Ferber G. Pharmacokinetics and pharmacodynamics of COX189 in patients with knee or hip primary osteoarthritis. Ann Rheum Dis 2002;61(Suppl. 1):128 [abstract THU0233]
11. Mangold JB, Gu H, Rodriguez LC, Bonner J, Dickson J, Rordorf C. Pharmacokinetics and metabolism of lumiracoxib in healthy male subjects. Drug Metab Dispos 2004;32:566-71
12. Day RO, Graham GG, Williams KM. Pharmacokinetics of non-steroidal anti-inflammatory drugs. Baillieres Clin Rheumatol 1988;2:363-93
13. Day RO, McLachlan AJ, Graham GG, Williams KM. Pharmacokinetics of nonsteroidal anti-inflammatory drugs in synovial fluid. Clin Pharmacokinet 1999;36:191-210
14. Weaver ML, Flood DJ, Kimble EF, Fujimoto RA. Lumiracoxib demonstrates preferential distribution to inflamed tissue in the rat following a single oral dose: an effect not seen with other cyclooxygenase-2 inhibitors. Ann Rheum Dis 2003;62 (Suppl. 1):378 [abstract AB0044]
15. Dawson J, Jagher B, Toscano KT, Fujimoto RA, Quadros E. Lumiracoxib shows rapid distribution to inflamed sites in a rat tissue chamber model compared with rofecoxib and celecoxib. Ann Rheum Dis 2003;62(Suppl. 1):377 [abstract AB0042]
16. Scott G, Rordorf C, Reynolds C, et al. Pharmacokinetics of lumiracoxib in plasma and synovial fluid. Clin Pharmacokinet 2004;43:467-78
17. Altman R, Asch E, Bloch G, et al. Development of criteria for the classification and reporting of osteoarthritis: classification of osteoarthritis of the knee. Arthritis Rheum 1986;29:1039-49
18. Altman R, Alarcon G, Appelrouth D, et al. The American College of Rheumatology criteria for the classification and reporting of osteoarthritis of the hip. Arthritis Rheum 1991;34:505-14
19. Arnett FC, Edworthy SM, Bloch DA, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315-24
20. Hochberg MC, Chang RW, Dwosh I, Lindsey S, Pincus T, Wolfe F. The American College of Rheumatology 1991 revised criteria for the classification of global functional status in rheumatoid arthritis. Arthritis Rheum 1992;35:498-502
21. Bellamy N, Buchanan WW, Goldsmith CH, Campbell J, Stitt LW. Validation study of WOMAC: a health status instrument for measuring clinically important patient relevant outcomes to antirheumatic drug therapy in patients with osteoarthritis of the hip or knee. J Rheumatol 1988;15:1833-40
22. Felson DT, Anderson JJ, Boers M, et al. American College of Rheumatology: preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum 1995;38:727-35
23. Dunnett CW. A multiple comparison procedure for comparing several treatments with a control. J Am Statist Assoc 1955;50:1096-121
24. Marcus R, Peritz E, Gabriel KR. On closed testing procedures with special reference to ordered analysis of variance. Biometrika 1976;63:655-60
25. Jeske AH. COX-2 inhibitors and dental pain control. J Gt Houst Dent Soc 1999;71:39-40
26. Po AL, Zhang WY. Analgesic efficacy of ibuprofen alone and in combination with codeine or caffeine in post-surgical pain: a meta-analysis. Eur J Clin Pharmacol 1998;53:303-11
27. Rordorf C, Kellett N, Mair S, et al. Gastroduodenal tolerability of lumiracoxib versus placebo and naproxen: a pilot endoscopic study in healthy male subjects. Aliment Pharmacol Ther 2003;18:533-41
28. Rubenstein JH, Laine L. Systematic review: the hepatotoxicity of non-steroidal anti-inflammatory drugs. Aliment Pharmacol Ther 2004;20:373-80